Engels D, Madaras T, Nyandwi S, Murray J
Programme for the Control of Diarrhoeal Diseases, Belgian Technical Cooperation, Burundi.
Bull World Health Organ. 1995;73(6):787-91.
Annual epidemics of bacillary dysentery have been a public health problem in Burundi for the last 14 years. Recent civil unrest, resulting in the displacement of large numbers of people into refugee settlements, has aggravated the situation. We report the results of a nationwide, health-centre based, sentinel site survey to check the drug resistance of Shigella dysenteriae type 1 (Sd1), the causal organism of such epidemics. Shigella spp. (of which 97% were Sd1) were isolated from 73% of the 126 specimens collected from six main sites around the country. There was no difference in culture results from fresh and frozen stool specimens. Overall Sd1 resistance to commonly available antibiotics (sulfamethoxazole + trimethoprim, ampicillin, tetracycline, and chloramphenicol) varied from 77% to 99% and was fairly uniformly distributed over the country. All Sd1 isolates were susceptible to newer drugs, such as ciprofloxacin and ceftriaxone. Resistance to nalidixic acid, the current first line of treatment for bacillary dysentery in Burundi, varied from 8% to 83% in the different sentinel sites; global resistance was 57%.
在过去14年里,细菌性痢疾的年度流行一直是布隆迪的一个公共卫生问题。最近的内乱导致大量人口流离失所,进入难民营,使情况更加恶化。我们报告了一项基于全国卫生中心的哨点调查结果,以检测引起此类流行的病原菌——痢疾志贺菌1型(Sd1)的耐药性。从全国六个主要地点采集的126份标本中,73%分离出志贺菌属(其中97%为Sd1)。新鲜和冷冻粪便标本的培养结果没有差异。总体而言,Sd1对常用抗生素(磺胺甲恶唑+甲氧苄啶、氨苄西林、四环素和氯霉素)的耐药率在77%至99%之间,且在全国分布相当均匀。所有Sd1分离株对新药物如环丙沙星和头孢曲松敏感。在不同哨点,对布隆迪目前治疗细菌性痢疾的一线药物萘啶酸的耐药率在8%至83%之间;总体耐药率为57%。